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Covid-19 pandemic presents particular challenges 
for people who are using drugs and for those 
providing services to vulnerable populations. 
Social distancing requirements are hampering 
effective operation of services and many treatment 
centres are temporarily closed. Many national and 
international organisations have highlighted the 
additional dangers faced by users of drugs services 
and have produced guidelines for drug treatment 
and harm reduction practitioners. 
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In brief
As this issue of Drugnet Ireland goes to print, we are in the 
11th week of the extraordinary measures introduced by the 
Government in response to the Covid-19 crisis. This global 
pandemic is affecting most of the world’s population in some 
way. Many have lost loved ones, are ill themselves, or enduring 
severe difficulties through loss of income. Most of the citizens 
of scores of countries across the world are largely confined to 
their own homes and many face the isolation of quarantine. 
Our healthcare workers and those in essential services face 
additional threats to their health every day. The gratitude 
expressed to them and the countless instances of kindness 
and care since this emergency began are reassuring signs of 
decency and a sense of community. These will be essential 
resources as we face the difficult months ahead.
We are also aware of the further dangers faced by socially excluded groups, 
already enduring poor health outcomes and having poor access to healthcare 
services. We know that restrictions in services and in contacts with vulnerable 
people are exacerbating the everyday life challenges faced by people with 
substance use problems. People who are homeless and people who use 
drugs often have multiple comorbidities and early mortality compared with 
the general population.1 The older cohort of opioid users are particularly 
vulnerable because of their high level of pre-existing health problems. There 
is a high prevalence of chronic obstructive pulmonary disease, asthma, and 
cardiovascular disease among people who inject drugs and use cocaine. 
These chronic medical conditions will put clients of drug treatment services 
at particular risk for serious respiratory illness if they become infected with 
Covid-19.
These are the marginalised groups most relevant to the concept of inclusion 
health. This is an approach to health service delivery and research that 
emphasises the need to arrange healthcare to improve outcomes for the most 
at-risk groups in society. At a time like this, we also recognise it is not just a 
social exclusion or human rights issue. The vulnerabilities of one group affect us 
all, and the current crisis will not pass until all are free from risk. The values that 
underpin the idea of inclusion health are essential to the idea of public health.
This is also a time in which we are keenly aware of the importance of accurate, 
scientifically based, and credible information. Evidence must be communicated 
freely and clearly so that all citizens can play their part in responding to the
crisis. International health institutions, monitoring agencies, and non-
governmental organisations have produced guidelines, assessments of the 
situation, and advice that will prove valuable to all those who provide services 
to those most at risk of harm from drug use. These organisations have been 
enabled to produce these resources because they draw on a solid base of 
knowledge created by epidemiologists, treatment specialists, and others in the 
health, social science, and policy fields.2 Using this evidence effectively will be 
essential to achieving good outcomes for our most marginalised citizens in the 
days and weeks ahead.
 
 
1 Ní Cheallaigh C, Cullivan S, Sears J, et al. (2017) Usage of unscheduled hospital care 
by homeless individuals in Dublin, Ireland: a cross-sectional study. BMJ Open, 7(11). 
https://www.drugsandalcohol.ie/28307/
2 The National Drugs Library has combined all the Covid-19-related material in its 
repository and made these available through a special link on the homepage of the 
library website. https://www.drugsandalcohol.ie/31779/
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Services have recognised that they have to adapt frontline 
services very quickly to prioritise and support the public health 
response to Covid-19. Tony Duffin, CEO of Ana Liffey Drug Project, 
which provides low threshold harm reduction support in Dublin 
and Limerick, explains:
We closed our drop-in services and stopped all 
group work as we could not maintain a safe physical 
distance for clients and staff. We focussed our efforts 
on working on outreach in the streets explaining 
Covid-19, providing our Needle & Syringe Programme 
and explaining how to stay safe on both counts. In 
the very early days of the Covid-19 crisis many of the 
people we met on outreach simply did not know about 
Covid-19, i.e. no knowledge of the latest advice, what 
the restrictions were or how the service provision 
landscape had changed. Our team spent a lot of time 
explaining the situation, supporting people around 
their fears & frustrations and getting them linked into 
treatment and housing options.1 
The Health Service Executive (HSE) has published guidelines 
for general practitioners and pharmacies providing services 
in regard to people who are at greater risk at this time.2 
These include those who have not yet commenced opiate 
substitution treatment; those who are homeless or in insecure 
accommodation; those at risk of overdose having acquired a 
greater than usual amount of drugs; or those who are using drugs 
alone. There are also increased risks from polydrug use, including 
alcohol and non-prescription medications, and practitioners have 
particular concerns in regard to failures to attend a prescriber or 
pharmacy as planned.
Impact of Covid-19   continued
POLICY AND LEGISLATION 
Ireland and the 
human rights of 
people who use drugs
The Ana Liffey Drug Project (ALDP) has published a report, 
Ireland and the human rights of people who use drugs,1 
that discusses the Government’s proposed health diversion 
approach (HDA) to the possession of drugs for personal use 
within the context of human rights.
Irish policy context
Ireland’s current national drugs strategy reflects a more human 
rights-based approach than previous strategies.2 While human 
rights are only specifically mentioned once in the document, 
features that indicate a strategy aligned with human rights 
include:
• It takes a health-led approach to drug use.
• It is underpinned by the values of compassion, respect, 
equity, inclusion, partnership, and evidence-informed.
• It incorporates human rights in some elements; for example, 
introducing supervised injecting facilities and exploring 
approaches to the possession of small quantities of drugs.
The ALDP report is specifically focused on this last element 
– responses to the possession of drugs for personal use. On 
2 August 2019, the Government announced the launch of the 
HDA to the possession of drugs for personal use. This approach 
offers alternatives to criminal prosecutions for the first two 
instances in which people are found in possession of drugs for 
personal use. Essentially, the action taken by An Garda Síochána 
(AGS) will depend on the number of times an individual has 
been caught in possession.
• On the first occasion, AGS will refer them, on a mandatory 
basis, to the Health Service Executive for a health screening 
and brief intervention.
• On the second occasion, AGS will have the discretion to 
issue an adult caution.
• On the third or any subsequent occasion, AGS will revert to 
dealing with the person in line with Section 3 of the Misuse 
of Drugs Act 1977, under which they could receive a criminal 
conviction and custodial sentence.
Aim of report
The exact detail of the HDA and how it will be implemented 
are topics currently under consideration by a governmental 
working group. The ALDP report aims to inform these 
considerations and to urge a rethinking of the proposed 
approach. It reflects on the HDA within the context of Ireland’s 
national and international human rights commitments and 
related literature.
The HSE guidelines suggest how the assessment process for 
potential opiate substitution treatment clients can be shortened 
and how assessments, clinical reviews, and prescription 
management can if necessary be undertaken remotely. 
Assistance for those who present with benzodiazepine or alcohol 
withdrawal symptoms is also covered. The guidelines also provide 
advice on what factors should be considered when doctors 
are making choices about medication and administration of 
naloxone, a drug that reverses the effects of opioid overdose. 
Merchants Quay Ireland, which manages low threshold services, 
are running brief sessions in its Dublin city centre premises, 
providing instructions on how to administer naloxone. 
It will be some time before the full impact of the global pandemic 
on people who use drugs will be fully known. It is important that 
we create a detailed picture of the changes in patterns of drug 
use and an understanding of how people are managing with 
reduced services. This population will have had to face a very 
distressing situation and threats to their physical and mental 
health. Our understanding of this will help to ensure that this 
population receives the attention it needs when preventive 
measures, such as vaccination programmes, are being put in 
place to avoid a recurrence of the Covid-19 catastrophe.
Brian Galvin
1 The Amsterdam-based Correlation network has compiled 
accounts from harm reduction services in many parts of Europe, 
including one provided by the Ana Liffey Drug Project. Available 
online at: https://www.correlation-net.org/sharing-experiences/
2 Health Service Executive (2020) Guidance on contingency 
planning for people who use drugs and COVID-19. Dublin: Health 
Service Executive. https://www.drugsandalcohol.ie/31804/
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Human rights
The report identifies three areas of human rights which it 
maintains are compromised by the ongoing criminalisation of 
possession for personal use:
1 The right to health – criminalisation creates barriers to 
accessing health services, for example.
2 The prohibition of discrimination – criminalisation validates 
and compounds the discrimination experienced by users in 
the workplace and their communities, for example.
3 The right to privacy – the right to privacy should include 
the right to use a drug in the privacy of one’s home, for 
example.
Under each of these areas, the authors cite international 
literature that highlights the often contradictory position of 
drug control laws versus health-based policy positions. For 
example, the ‘inherent conflict between the right to health in 
the context of the UN human rights treaties on the one hand, 
and the implementation of the UN drug control regime on the 
other hand’ (p. 8).
Proportionality
Proportionality is a general principle in criminal law which 
focuses on the idea that the severity of a punishment should 
reflect the gravity of the crime. In the context of human 
rights, it is recognised that individual rights may sometimes 
need to be restricted by policy or law to maintain a ‘larger or 
more important imperative – such as national security’ (p. 
13). The report argues that in this context the HDA is not a 
proportionate policy response. First, it will make attendance 
at a health assessment mandatory – a response described as 
‘coercive’ and in contrast to policy responses to all other health 
issues. More broadly, the criminalisation of possession itself is 
seen to lack proportionality. The authors argue that ‘there is no 
reliable “greater good” argument …. criminalisation of simple 
possession does not deter people from using drugs in any 
meaningful or consistent way’ (p. 13). 
The lack of proportionality is seen to be reinforced when 
considering the negative impacts of criminalisation for the 
user. For example, the long-term negative consequences on a 
person’s housing and employment opportunities. The report 
cites the Global Commission on Drug Policy:
Punitive drug law enforcement is predicated on 
the idea that criminalization serves as a deterrent. 
Notwithstanding its popularity, this theory is not 
supported by evidence. Instead, research indicates 
that criminalizing drug users actually worsens drug-
related problems.3
Irish Human Rights and Equality  
Commission Act 2014
In 2014, Ireland became the first European Union member state 
to introduce legislation that combines equality and human 
rights as a ‘public sector duty’. This public sector duty requires 
public bodies to take proactive steps to promote equality, 
protect human rights, and fight discrimination in relation to 
their functions and powers.4 Section 42 of the Irish Human 
Rights and Equality Commission Act 2014 (IHREC) states:5
(1) A public body shall, in the performance of  
its functions, have regard to the need to:
(a) eliminate discrimination,
(b) promote equality of opportunity and treatment 
of its staff and the persons to whom it provides 
services, and
(c) protect the human rights of its members, staff  
and the persons to whom it provides services.
ALDP concludes that the HDA will not be supportive of the 
public bodies responsible for executing the policy in also 
fulfilling their statutory obligations under the above elements  
of the IHREC Act 2014.
Conclusions
Overall, the report is critical of the HDA and argues that it is not 
compatible with a human rights-based approach to policy. At 
its core, the report argues that the proposed HDA will continue 
to marginalise and stigmatise those experiencing the most harm 
through their substance use – the most habitual users would 
be at the most risk of being criminalised for possession on the 
third or any subsequent occasion. It is therefore seen by ALDP 
as being contradictory to Ireland’s national drugs strategy; while 
drug use is seen as a health issue in the strategy, the HDA will 
perpetuate the criminalisation of users. Furthermore, they 
see it as unsupportive of the public bodies’ obligations under 
Section 42 of the IHREC Act 2014.
Lucy Dillon
1 Scharwey M, Keane M and Duffin T (2019) Ireland and the human 
rights of people who use drugs. Dublin: Ana Liffey Drug Project. 
https://www.drugsandalcohol.ie/31427/
2 Department of Health (2017) Reducing harm, supporting recovery: 
a health-led response to drug and alcohol use in Ireland 
2017–2025. Dublin: Department of Health.  
http://www.drugsandalcohol.ie/27603/
3 Global Commission on Drug Policy (2014) Taking control: pathways 
to drug policies that work Geneva: Global Commission on Drug 
Policy. https://www.drugsandalcohol.ie/22611/
4 Equality and Rights Alliance (2015) A new public sector: equality 
and human rights duty. Dublin: Equality and Rights Alliance. 
http://www.eracampaign.org/uploads/A%20New%20Public%20
Sector%20Duty%20March%202015.pdf
5 Irish Human Rights and Equality Commission Act 2014. Available 
online at:  
http://www.irishstatutebook.ie/eli/2014/act/25/enacted/en/html
Human rights of people  
who use drugs   continued
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Guidance on human 
rights for health and 
social care services 
in Ireland
On 13 November 2019, the Health Information and Quality 
Authority (HIQA), in conjunction with Safeguarding Ireland, 
published Guidance on a human rights-based approach in health 
and social care services.1 Its overall purpose is to ‘promote a 
human rights-based approach to care and support for adults in 
health and social care services’ (p. 4),1 including those working in 
the addiction services. Taking a human rights-based approach 
to the delivery of care services is a requirement of public body 
staff and organisations under the Irish Human Rights and Equality 
Commission Act 2014, where Section 42 of the Act created a 
‘public sector duty’ that requires public bodies to take proactive 
steps to promote equality, protect human rights, and fight 
discrimination in relation to their functions and powers.2 However, 
practitioners experienced difficulties with translating the principles 
of human rights into their day-to-day practice and service 
delivery. HIQA’s guidance aims to bridge that gap.
Guidance structure
The guidance was developed based on a review of national 
and international best practice and through consultation with 
stakeholders. It provides an overview of what human rights are 
and how they apply to those working in health and social care 
services. The main body of the report is structured around a set of 
five principles, under each of which is the relevant human rights-
related legislation, examples of how service providers can support 
and promote the principle in their work, and illustrations provided 
through the use of case studies. While service providers are the 
primary audience for the guidance, HIQA suggests that it should 
also be of value to service users by building their understanding 
of what to expect from any service grounded in a human rights-
based approach.
FREDA principles
Based on their review of international best practice, the authors 
chose to structure the guidance around a set of principles 
associated with human rights. They use the FREDA principles, 
which they describe as ‘an internationally recognised framework 
through which human rights can be considered’ (p. 11).1 The 
five principles as laid out in the guidance are: fairness, respect, 
equality, dignity, and autonomy (FREDA).
• Fairness means ensuring that when a decision is made with 
a service user about their care and support that the person 
is at the centre of the decision-making process.
• Respect is the objective, unbiased consideration and 
regard for the rights, values, beliefs, and property of other 
people. It applies to the person as well as to their value 
system.
• Equality means people having equal opportunities and 
being treated no less favourably than other people on the 
grounds set out in legislation. In an Irish context, these 
grounds are: age; civil status; disability; family status; 
gender; membership of the Traveller community; race; 
colour or nationality; religion or sexual orientation.
• Dignity means treating people with compassion and in a 
way that values them as human beings and supports their 
self-respect, even if their wishes are not known at the time.
• Autonomy is the ability of a person to direct how they 
live on a day-to-day basis according to personal values, 
beliefs, and preferences. In a health and social care setting, 
autonomy involves the service user making informed 
decisions about their care, support, or treatment.
Conclusion
The HIQA guidance sets out to support organisations and staff 
by translating human rights theory into practice and therefore 
supporting them in complying with their public sector equality and 
human rights duty.2 While the case studies and illustrations used in 
the guidance are not specifically in the area of addiction services, 
the principles should be transferable to any health and social care 
service.
Lucy Dillon
1 Health Information and Quality Authority (HIQA) (2019) Guidance 
on a human rights-based approach in health and social care 
services. Dublin: HIQA. https://www.drugsandalcohol.ie/31418/
2 Section 42 of the Irish Human Rights and Equality Commission 
Act 2014 states: ‘(1) A public body shall, in the performance of its 
functions, have regard to the need to: (a) eliminate discrimination, 
(b) promote equality of opportunity and treatment of its staff and 
the persons to whom it provides services, and (c) protect the 
human rights of its members, staff and the persons to whom it 
provides services’. Irish Human Rights and Equality Commission 
Act 2014. Available online at:  
http://www.irishstatutebook.ie/eli/2014/act/25/enacted/en/html
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Inclusion Strategy
In November 2019, the Department of Justice and Equality 
published the National LGBTI+ Inclusion Strategy 2019–2021.1 As 
with the National LGBTI+ Youth Strategy 2018–2020,2 the new 
strategy aims to provide a strategic framework for ‘identifying 
and addressing issues which may prevent LGBTI+ people from 
enjoying full equality in practice in Irish society’ (p. 3).1 The 
strategy provides a structure in which:
• LGBTI+ groups can identify issues that persist in creating an 
environment of inequality.
• Government, public agencies, business groups, employer 
and employee representatives, and civil society can work 
together to resolve these issues.
It is structured around four thematic pillars, under each of 
which are a set of outcomes to be achieved and a set of 
associated actions.
Vision and mission
Vision: A safe, fair and inclusive Ireland where people are 
supported to flourish and to live inclusive, healthy, and fulfilling 
lives, whatever their sexual orientation, gender identity or 
expression, or sex characteristics.
Mission: To promote inclusion, protect rights, and to improve 
quality of life and wellbeing for LGBTI+ people enabling them 
to participate fully in Ireland’s social, economic, cultural, and 
political life.
Thematic pillars
The four thematic pillars are based on stakeholder consultation 
about what issues LGBTI+ people in Ireland were facing.
Visible and included: This pillar focuses on the need for 
increased visibility and non-stereotypical representation of 
LGBTI+ identities, which would support long-term attitudinal 
change. Among the eight outcomes identified under this pillar 
were: LGBTI+ people are positively visible across all sectors of 
society; Irish workplaces are inclusive of LGBTI+ people and 
support them in bringing their ‘authentic selves’ to work; and 
better information is available on the population and needs 
of LGBTI+ people in Ireland to support the development of 
effective policy.
Treated equally: This pillar has at its core legislative change 
and awareness raising to ensure that LGBTI+ people are treated 
equally. Among the five outcomes to be achieved are: LGBTI+ 
people are aware of the supports and redress mechanisms 
available to them where discrimination has occurred; same-sex 
parents are treated equally to opposite-sex parents before the 
law; supports are provided to those at higher risk of multiple 
discrimination and marginalisation, including older people, 
migrants, Travellers, people with disabilities, and prisoners 
among the LGBTI+ community.
Healthy: The strategy commits to ensuring that LGBTI+ people 
can fully and equally avail of mainstream health services, while 
also recognising the need for dedicated services in some 
circumstances. Among the seven outcomes to be achieved 
are: healthcare providers and practitioners are trained to 
understand the identities and needs of their LGBTI+ patients 
and to avoid making heteronormative assumptions; and people 
living with HIV in Ireland are supported and not stigmatised. 
The action in Reducing harm, supporting recovery: a health-
led response to drug and alcohol use 2017–20253 aimed at 
addressing the needs of LGBTI+ people is cited as an action 
under the following outcome: health policy takes consideration 
of the needs of all population groups, including the LGBTI+ 
community.
Safe and supported: The strategy intends to ensure that 
LGBTI+ people feel safe and secure when living their daily 
lives. Among the six outcomes linked to this pillar are: Ireland 
has strong legislation and supports in place to combat hate 
crime and encourages people to report it; LGBTI+ victims of 
crime are appropriately supported and included in mainstream 
service provision underpinned by formalised consultation 
structures with An Garda Síochána and other relevant agencies; 
and LGBTI+ people can travel safely and with confidence.
A mid-term report on progress made on implementing the 
strategy will take place in Q3 of 2020.
Lucy Dillon
1 Department of Justice and Equality (2019) National LGBTI+ 
Inclusion Strategy 2019–2021. Dublin: Government of Ireland. 
https://www.drugsandalcohol.ie/31368/
2 Department of Children and Youth Affairs (2018) LGBTI+ National 
Youth Strategy 2018–2020. Dublin: Department of Children and 
Youth Affairs. https://www.drugsandalcohol.ie/29267/
3 Department of Health (2017) Reducing harm, supporting recovery: 
a health-led response to drug and alcohol use in Ireland 
2017–2025. Dublin: Department of Health.  
https://www.drugsandalcohol.ie/27603/
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PREVALENCE AND CURRENT SITUATION 
Health in Ireland  
– key trends
The Department of Health has published the 12th edition of 
Health in Ireland: Key trends 2019.1 Using data from newly 
available sources, the report highlights selected trends in drug, 
alcohol, and tobacco consumption as well as the number of 
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Figure 1: Percentage of children, aged 11-17 years, engaged in risky health behaviours in Ireland, 2010, 2014, and 2018
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Figure 2: Alcohol and cigarette consumption per annum, per capita aged 15 years and over, 1998–2018
individuals entering treatment in Ireland for problem drug and 
alcohol use between 2009 and 2018.
Smoking, alcohol, and cannabis use
Figure 1 shows the percentage of Irish children, aged 11–17 
years, who engaged in risky health behaviours for the years 
2010, 2014 and 2018. Findings demonstrate that there has been 
a constant downward trend in the percentage of children who 
smoked cigarettes monthly or frequently, who had ever used 
alcohol, and who had used cannabis in the last year. Similarly, 
there has been a downward trend in alcohol and cigarette 
consumption among adults aged 15 years and over between 
1998 and 2018 (see Figure 2).
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% Change
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2009 
-2018
2017 
-2018
Drugs including alcohol
All cases in 
treatment 15,092 16,422 16,827 16,126 16,312 17,077 16,933 16,325 15,742 17,093 13.3 8.6
New entries 
into treatment 
each year
7,517 7,738 7,719 7,114 6,899 7,237 7,007 6,922 6,482 6,889 –8.4 6.3
Rate per 
100,000 
(15–64- 
year-olds)
242.6 250.9 251.7 232.9 226.1 236.5 227.8 223.0 206.7 216.9 –10.6 4.9
Drugs excluding alcohol
All cases in 
treatment 7,389 8,699 8,283 7,903 8,894 9,672 9,711 9,097 8,772 10,113 36.9 15.3
New entries 
into treatment 
each year
3,359 3,657 3,265 3,191 3,389 3,648 3,651 3,446 3,168 3,859 14.9 21.8
Rate per 
100,000 
(15–64- 
year-olds)
108.4 118.6 106.5 104.4 111.1 119.2 118.7 111.0 101.0 121.5 12.1 20.3
Table 1: Number of cases in treatment for problem drug and alcohol use and rate per 100,000 population aged 15–64 years in Ireland, 
2009–2018
Source: Department of Health (2019)
Health in Ireland – key trends   
continued
Treatment for problem drug and alcohol use
Table 1 shows the number of individuals entering treatment for 
problem alcohol or drug use between 2009 and 2018. There 
were 17,093 cases treated in 2018, representing a rate of 217 
people per 100,000 aged 15–64 years. This is an increase of 
8.6% compared with 2017, when there were 15,742 individuals 
in treatment. However, figures show that this rate peaked in 
2011 at 251.7 per 100,000 aged 15–64 years and has been slowly 
decreasing ever since.
Seán Millar
1 Department of Health (2019) Health in Ireland: Key trends 2019. 
Dublin: Government of Ireland.  
https://www.drugsandalcohol.ie/31508/
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Fatality study of 
drugs taken in 
intentional overdose 
in Ireland
Intentional drug overdose (IDO) is the most common method of 
hospital-presenting, non-fatal self-harm1 and has been linked 
with an increase in premature mortality risk due to suicides, 
accidents, and other causes.2 Importantly, the risk of mortality 
due to suicide is increased among persons who have engaged 
in IDO and in 2018 intentional overdoses resulted in 7,792 
presentations to Irish hospitals.3 Multiple drugs are present in 
between 26% and 41% of non-fatal IDOs, increasing to 64% in 
fatal overdoses.4,5,6 Nevertheless, despite the involvement of 
multiple drugs in IDO, the case fatality of drugs taken in multiple 
drug overdoses remains under-researched and little is known 
about how case fatality risk varies according to the type of 
drug(s) taken.
A recent Irish study aimed to examine the incidence of IDO in 
Ireland, to identify the predictors of fatal IDO, and to establish 
which drugs are linked with greater risk of a fatal outcome.7 In 
this research, published in the International Journal of Drug 
Policy, data from the National Self-Harm Registry and the 
National Drug-Related Deaths Index, 2007–2014, were used to 
calculate incidence, to examine overdose characteristics, and 
to estimate case fatality risk ratios.
There were 63,831 non-fatal and 364 fatal IDOs during this 
period (incidence: 148.8 and 1.01 per 100,000, respectively). 
Compared with non-fatal IDOs, fatal cases were more likely 
to be male (55.2% vs 42%), were older in age (median 44 vs 35 
years), and more frequently involved multiple drugs (78.3% vs 
48.5%). The study found that tricyclic antidepressants were 
associated with a 15-fold increased risk of death, while opioids 
were associated with a 12-fold increased risk, relative to the 
reference category (non-opioid analgesics). While the risk of 
fatal outcome was higher for males than females, the elevation 
in risk was greater in females when tricyclic antidepressants or 
opioids were taken.
As tricyclic antidepressants and opioids were found to be 
associated with a significantly increased risk of death, the 
authors concluded that these results add to the current 
evidence regarding the risk and potential adverse outcomes 
associated with these drugs. Findings may help inform safe and 
appropriate prescribing, where clinicians consider the fatality 
risk of drugs when determining treatment for patients at risk of 
self-harm, or who have previously harmed themselves.
Seán Millar
1 Perry IJ, Corcoran P, Fitzgerald AP, Keeley HS, Reulbach U, et al. 
(2012) The incidence and repetition of hospital-treated deliberate 
self harm: findings from the world’s first national registry. PloS One 
7(2): e31663.
2 Finkelstein Y, Macdonald EM, Hollands S, Hutson JR, Sivilotti 
MLA, Mamdani MM, et al. (2015) Long-term outcomes following 
self-poisoning in adolescents: a population-based cohort study. 
Lancet Psychiatry, 2(6): 532–539.
3 Griffin E, McTernan N, Wrigley C, Nicholson S, Arensman E, 
Williamson E, et al. (2019) National Self-Harm Registry Ireland: 
annual report 2018. Cork: National Suicide Research Foundation. 
https://www.drugsandalcohol.ie/31193/
4 Daly C, Griffin E, Ashcroft DM, Webb RT, Perry IJ and Arensman 
E (2018) Frequently used drug types and alcohol involvement in 
intentional drug overdoses in Ireland: a national registry study.  
Eur J Public Health, 28(4): 681–686.  
https://www.drugsandalcohol.ie/28709/
5 Finkelstein Y, Macdonald EM, Hollands S, Sivilotti MLA, Hutson JR, 
Mamdani MM, et al. (2015) Risk of suicide following deliberate self-
poisoning. JAMA Psychiatry, 72(6): 570–575.
6 Health Research Board (HRB)(2015) National Drug-Related Deaths 
Index 2004 to 2015 data. Dublin: Health Research Board.  
https://www.drugsandalcohol.ie/28086/
7 Daly C, Griffin E, Corcoran P, Webb RT, Ashcroft DM, Perry IJ and 
Arensman E (2020) A national case fatality study of drugs taken in 
intentional overdose. Int J Drug Policy, 76: 102609.
Blanchardstown Drug 
and Alcohol Trends 
Monitoring System
The Blanchardstown Local Drug and Alcohol Task Force 
(BLDATF) is one of 14 local drug and alcohol task forces 
(LDATFs) established in 1997 in response to high levels of drug 
misuse within Irish communities. BLDATF is responsible for 
implementing the National Substance Misuse Strategy1 and 
facilitating a more coordinated response in tackling drug and 
alcohol use and misuse in Dublin 15. In order to adapt and 
change services in a thorough and comprehensive manner, the 
Blanchardstown Drug and Alcohol Trends Monitoring System 
(DATMS) was established in 2015 to provide a better knowledge 
of drug-related harms in the area. The specific objective of 
DATMS is to establish an evidence base for drug use in Dublin 15 
and use these data to inform local service provision.
A recent report documents Year 4 of DATMS.2 The Year 1 
reporting period began in June 2014; Year 2 began in June 
2015; Year 3 relates to 2017; and Year 4 to 2018. The DATMS 
report employs a mixed-method design comprising primary 
and secondary data sources. Key findings from the report are 
discussed below.
Treated drug use
Treated cases aged 18 years and under increased from 51 in 
Year 1 to 97 in Year 4, with 1% of the Dublin 15 population aged 
12–17 years having attended treatment for drug and/or alcohol 
use. From Year 1 to Year 4, the profile of treated cases has 
remained similar, with a majority being Irish and male. Cannabis 
herb was found to be the most commonly used drug among this 
age group, followed by alcohol, with a majority of cases being 
polydrug users.
Among subjects aged 18 years and over, there was an increase 
in the number of treated cases from 292 in 2016 to 348 in 
2018. The majority of treated cases were Irish, male, and aged 
35–44 years. One-third of cases were in treatment for drugs 
for the first time and the three main problem drugs reported 
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were alcohol, heroin, and cocaine. Changes in the profile of 
treated drug users included an increase in the use of cannabis 
herb, alcohol, powder and crack cocaine, benzodiazepines, 
and Z-drugs. Year 4 also reported an increase in the use of 
pregabalin, heroin, and cannabis oil.
Untreated drug use
All four years of DATMS reported similar profiles of untreated 
drug use by young people and adults, with alcohol, cannabis 
herb, ecstasy, and cocaine powder being the main drugs 
used and polydrug use being the norm. Changes in the profile 
of untreated drug users included an increase in the use of 
alcohol, cannabis herb and oil, powder and crack cocaine, 
benzodiazepines, and Z-drugs, and that untreated drug users 
were getting younger.
Normalisation of drug use
The report notes that there are two recurring themes emerging 
from the different data sources over four years. First, that drug 
use in Dublin 15 is a community-wide issue that crosses all 
socioeconomic boundaries, as treated drug users were from 
every community in Dublin 15, from the affluent to the deprived. 
Second, that drug use in Dublin 15 has become normalised. The 
common perception among study participants was that alcohol 
and drugs are widely used, risk free, and socially acceptable. 
Alcohol was found to be the most normalised drug in Dublin 
15, followed by cannabis, cocaine powder, benzodiazepines, 
and Z-drugs. Importantly, all four years of DATMS reported the 
family context as a risk factor for the normalisation of drug and 
alcohol use and the development of intergenerational drug and 
alcohol dependence. The majority of treated drug users who 
participated in Years 3 and 4 reported having family members 
who also had issues with drugs and/or alcohol.
Recommendations for service provision
The report notes the gaps in service provision identified by 
study participants and makes a number of recommendations. 
These include the following:
• Improve drug prevention programmes for people under 18 
years of age.
• Increase access to skills-based mental health wellbeing 
programmes for young people and adults.
• Provide education and information for family members 
about the latest drug trends.
• Improve treatment programmes for under 18s and young 
people.
• Improve access to naloxone, the antidote to opioid 
overdoses.
• Develop a stabilisation programme for non-opioid polydrug 
users.
• Increase access to mental health services for children, 
young people, and adults.
• Improve access to aftercare services, training, employment, 
and housing.
Seán Millar
1 Department of Health (2012) Steering Group Report on an 
National Substance Misuse Strategy. Dublin: Department of 
Health. https://www.drugsandalcohol.ie/16908
2 Blanchardstown Local Drug and Alcohol Task Force (BLDATF) (2019) 
Drug and Alcohol Trends Monitoring System (DATMS) 2019: year 4. 
Dublin: BLDATF. https://www.drugsandalcohol.ie/31485/
RECENT LEGISLATION
Judicial Council  
Act 2019
The Judicial Council Act 2019 was enacted on 23 July 2019.1 
The Act provides for the establishment of a Judicial Council. 
The council, which will be an independent body, will promote 
and maintain excellence and high standards. In addition, it will 
provide a statutory basis for the training of judges and for the 
investigation of complaints against judges. Under the provisions 
of the Act, the Judicial Council will also be responsible for 
establishing several subcommittees.
Judicial Studies Committee
Under Section 17 of the Act, the Judicial Studies Committee 
will be responsible for preparing and distributing information 
relevant to judges. In addition, it will facilitate the continuing 
education and training of judges regarding their function.
Personal Injuries Guidelines Committee
Under Section 18, the Judicial Council is required to establish 
a Personal Injuries Guidelines Committee within three months 
of the council’s establishment. This committee will consist 
of seven judges put forward by the Chief Justice. Each judge 
will be required to submit draft guidelines and amendments 
for personal injuries for appropriate general damages for 
various types of personal injury within six months of its 
commencement. Following completion of the first review, a 
follow-up review of the guidelines is required within three 
years, and once every three years thereafter.
Sentencing Guidelines and Information 
Committee
Under Section 23, within six months of the first Judicial Council 
meeting, the council is required to establish a Sentencing 
Guidelines and Information Committee. Under the provisions  
of the Act, the committee shall:
• Prepare and submit draft sentencing guidelines and 
amendments to sentencing guidelines adopted by the 
council to the board for review.
• Monitor the operation of sentencing guidelines.
• Collate and disseminate sentencing data to judges and 
other relevant individuals.
11
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Under Section 24, the committee will consist of 13 members: 
eight judges put forward by the Chief Justice, one of which will 
act as chairperson, and five lay members, who will be appointed 
by the Government.
Under Section 29, the Minister for Justice and Equality is 
required to begin a review of all legislation that provides for 
the imposition of minimum sentences for offences. The review 
must consider whether minimum sentences are imposed 
correctly and at what level of imposition. The findings must be 
submitted by the Minister to both Houses of the Oireachtas 
within 12 months of the review starting.
Judicial Support Committees
Under Section 30, five Judicial Support Committees will be 
established, namely:
• Supreme Court Judicial Support Committee
• Court of Appeal Judicial Support Committee
• High Court Judicial Support Committee
• Circuit Court Judicial Support Committee
• District Court Judicial Support Committee.
These will be available to each of the courts to advise and assist 
the Judicial Council in the performance of its functions.
Judicial Conduct Committee
Under Section 43, the Judicial Council is required to establish 
the Judicial Conduct Committee to promote and maintain 
high standards of conduct among judges relating to principles 
of judicial conduct requiring judges to uphold and exemplify 
judicial independence, impartiality, integrity, propriety 
(including the appearance of propriety), competence, and 
diligence, and to ensure equality of treatment to all persons 
before the courts. This committee will investigate complaints 
against judges and refer them for resolution by informal 
means. It is required to prepare and submit a review draft of 
guidelines for judicial conduct, including guidance on when a 
judge should recuse him or herself from presiding over legal 
proceedings.
Under this Act, the Judicial Conduct Committee is considered 
independent in the performance of its functions and shall 
have such powers deemed necessary or useful to carry out 
its functions. It may obtain legal, medical, or other advice in 
connection with performing its functions and may bring or 
defend legal proceedings or any other act or thing necessary 
for the performance of its functions.
Conclusion
Minister for Justice and Equality Charlie Flanagan TD believes 
that the enactment of this Act is a ‘landmark development’, 
which will help to ‘shape the way in which our judiciary 
operates at all levels by promoting consistent standards of 
excellence, preserving the very valuable confidence that the 
public has in our judiciary and in the administration of justice 
in this country’.2
Ciara H Guiney
1 Judicial Council Act 2019. Available online at:  
http://www.irishstatutebook.ie/eli/2019/act/33/enacted/en/html
2 Department of Justice and Equality (2019) Minister Flanagan 
announces the passage of the landmark Judicial Council Bill.  
9 July. Available online at:  
http://www.justice.ie/en/JELR/Pages/PR19000187
Misuse of Drugs 
(Prescription and  
Control of Supply of 
Cannabis for Medical 
Use) Regulations 2019
A statutory instrument, SI No. 262/2019 – Misuse of Drugs 
(Prescription and Control of Supply of Cannabis for Medical 
Use) Regulations 2019, was signed on 26 June 2019. These 
regulations allow for the use of certain cannabis products for 
the treatment of persons with certain medical conditions when 
under the care of a medical consultant.
Prescription and supply under the Cannabis  
for Medical Use Register
Part 2 of the Regulations provides for the prescription and 
supply of cannabis under the Cannabis for Medical Use Register 
(CMUR):
• Under Section 4 of the Regulations, a practitioner 
prescribing cannabis must be a medical consultant, must 
include their name and address on the prescription, and 
must continue to be responsible for and supervise the 
patient while being treated. In addition, only a person 
named on the CMUR who has been given a CMUR number 
from the Health Service Executive (HSE) can be issued a 
prescription.
• Under Section 4(6), when a prescription is being issued for 
the first time:
- It must be intended to treat the person for a specific 
condition.
- The HSE must be provided with the person’s name, 
address, date of birth, and the name of the condition 
being treated; the notifying practitioner’s name, 
registration number, and medical speciality; and any 
other information required by the HSE.
• Section 5 of the Regulations provides for the establishment 
and maintenance of the CMUR. The CMUR records the 
information provided by the practitioner under Section 
4(6). The HSE can alter or delete an entry; however, it may 
need additional information from the medical consultant 
supervising the treatment. The HSE is also responsible for 
assigning the CMUR number to each person entered in the 
register.
Recent legislation   continued
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• Under Sections 6 and 7, only a pharmacist or a person 
operating a retail pharmacy business shall supply a  
specified controlled drug to a practitioner. These  
suppliers must maintain records of the following:
- Date of supply
- Name of drug, quantity, and dosage
- Name, address, and registration number of the 
prescriber
- CMUR number
- Name and address of the person who is being  
prescribed the drug
- Date of prescription.
Commercial supply under licence
Part 3 of the Regulations provides for the commercial supply  
of cannabis under licence.
• Under Sections 11 and 12, a specified controlled drug should 
only be supplied to a pharmacist, retail pharmacy business, 
or hospital. For each consignment supplied, the supplier 
must maintain a record of each consignment received 
and supplied for a minimum of five years. The following 
information should be recorded:
- Name of the drug, including the brand name
- Dosage form of the drug
- Quantity of drug received and supplied
- Batch number of the drug received
- Name and address of the producer of that specified 
controlled drug in the form it was received
- Name and address of the supplier of each consignment.
This information should be made available to the Minister for 
Health when requested for review.
• Section 13 prohibits the exportation of imported specified 
controlled drugs outside of the State.
This legislation provides for the operation of the Medical 
Cannabis Access Programme on a pilot basis for five years.
Reporting, enforcement, and advertising
Part 4 of the Regulations provides for the reporting, 
enforcement, and advertising of a specified controlled drug 
within the scope of Part 2 or Part 3. Under Section 15, a person 
shall report suspected adverse reactions and quality defects 
to the Health Products Regulatory Authority (HPRA) within 15 
days of being provided with the information. Where there are 
quality or safety issues relating to a specified controlled drug 
or batch, HPRA can authorise the withdrawal or recall of the 
product (Section 16). If notice is received from the Minister for 
Health or HPRA to stop prescribing, supplying, or importing a 
specified drug, the specified controlled drug should no longer 
be supplied or imported (Section 17). Under Section 18, the 
advertisement or supply of information related to a specified 
controlled drug to the general public is restricted.
Ciara H Guiney
1 Misuse of Drugs (Prescription and Control of Supply of Cannabis 
for Medical Use) Regulations 2019. Available online at:  
http://www.irishstatutebook.ie/eli/2019/si/262/made/en/print
Recent legislation   continued
Parole Act 2019
The Parole Act 2019 was enacted on 23 July 2019.1 The purpose 
of the Act is to confer responsibility for granting parole upon an 
independent statutory body. It is divided into three parts. Part 
1 addresses preliminary and general matters; Part 2 addresses 
the Parole Board, its powers, and compositions; and Part 3 
deals with parole applications, guiding principles, and the 
parole process.
Part 2 of Act
Section 8 of the Act provides for the establishment of the 
Parole Board (known as An Bord Parúil). The board will 
function independently and on a statutory basis. The functions 
conferred on the board will include:
• Providing information to persons serving sentences of 
imprisonment, victims, and members of the public in 
relation to its functions
• Providing information to the Minister for Justice and 
Equality in relation to the functions of the board
• Making recommendations upon the request of the Minister 
to help him or her coordinate prisoners released on parole 
and draw up policy related to prisoners released on parole
• Undertaking or assisting in research projects that may 
inform how the board operates and assist the Minister in 
decision-making.
Section 13(1) provides the board with powers that are deemed 
necessary to carry out its functions. Under this section the 
board will be able to:
• Authorise written reports from appropriate individuals 
related to specific individuals.
• Assign a legal representative to the relevant person if they 
do not already have one during deliberations of parole 
application or parole order revocations.
• Interview a relevant person and receive oral submissions 
from him/her or his/her legal representative.
• Receive written arguments from a relevant person or his/
her legal representative.
• Assign a legal representative to the relevant victim where he 
or she wishes to put forward arguments to the board.
• Meet with a relevant victim to receive oral or written 
arguments from him/her or his/her legal representative.
• Apply to the Courts Service to obtain a transcript of a court 
hearing that was held in sentencing deliberations of the 
offender.
For the purpose of considering parole applications, variations 
to conditions or release dates outlined in a public order or 
revocations of a parole order, under Section 13(2) the board 
has the power to request written reports by or on behalf of 
Irish justice agencies or clinicians working with applicants. 
When a report is requested under this section, the board will 
outline all matters that need to be addressed in the report. It 
13
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may include one or more of the following: sentence details; 
conduct of applicant; risk or likelihood of reoffending; ability 
to comply with conditions outlined in the parole order; level 
of rehabilitation achieved thus far; ability to reintegrate into 
society; and risk to the public or victim. Parole will only be 
granted if the prisoner does not pose an undue risk to the 
public.
Part 3 of Act
Part 3 of the Act outlines the parole process. For example, 
under Section 24(1), eligibility for parole for individuals serving 
life imprisonment sentences has increased from 7 years to 12 
years. For individuals who are serving prison sentences that 
exceed those outlined in the regulations, following engagement 
with the board, the Minister may impose imprisonment of not 
less than 8 years, and the portion of imprisonment that needs 
to be served by a person before eligible for parole.
In some circumstances, individuals may not be eligible for 
parole. For example, in relation to drug offences, under Section 
24(12), where an individual is serving a specified minimum 
sentence of imprisonment under Section 27(3A) of the Misuse 
of Drugs Act 1977, pursuant to subsection (3C) or (3F) or that 
section, he/she shall not be eligible for parole before the 
minimum term has expired. Where parole applications have 
been refused or revoked, applicants will not be eligible to 
reapply for parole prior to the date specified by the board 
(Section 24(5) and (6)).
Conclusion
This legislation has been welcomed by Minister for Justice and 
Equality Charlie Flanagan TD, who views it as a ‘ground-breaking 
piece of legislation’ that will ensure that the way decisions are 
made by the Parole Board are ‘open, transparent, fair and fully 
informed’.2 The Irish Penal Reform Trust has long campaigned 
for the establishment of an independent Parole Board. Its 
executive director, Fíona Ní Chinnéide, has stated that this 
legislation will ‘provide more clarity and independence in 
decision-making on the release of eligible prisoners’.2
Ciara H Guiney
1 Parole Act 2019. Available online at: http://www.irishstatutebook.
ie/eli/2019/act/28/enacted/en/print#part3
2 Staines M (2019) People sentenced to life in prison must serve at 
least 12 years under new law. Newstalk. 11 July. Available online at: 
https://www.newstalk.com/news/life-sentence-parole-881671
Provisional review 
of road collision 
fatalities
On 3 January 2020, the Road Safety Authority (RSA) published 
a provisional review of fatal collisions for 2019.1,2 The report is 
the result of analysis of fatality data received from An Garda 
Síochána. The results in this analysis are provisional and may 
be subject to change. The report first provides an overview 
followed by more in-depth analysis by month of year; day of 
week; time of day; where fatalities occurred; age profile; road 
user type; and age profile by road user type. Drugs were not 
mentioned in this analysis.
Overview
Figure 1 shows the trends in fatalities from 1997 to 2019. In 2019, 
148 fatalities arose from 137 collisions on Irish roads.
Month of year
The highest number of fatalities were reported in March 
2017 (n=20) and September 2019 (n=20). The lowest number 
of fatalities were reported in May 2018 (n=5). In 2019, the 
most dangerous month was September (n=20), followed by 
December (n=16), January (n=14), and February (n=14).
Day of week and time of day
Figures 2 and 3 show what day of the week and what time of 
day the fatalities occurred. The highest number of fatalities was 
reported for Sunday in both 2018 and 2019. The data for 2019 
were higher for Thursday, Friday, Saturday, and Sunday when 
compared with 2018. Tuesday and Wednesday were shown to 
have the lowest number of fatalities in 2019; these figures were 
lower than those reported in 2018.
Data for 2019 indicated that the worst time for fatalities in Ireland 
was between 6pm and 8pm followed closely by 2pm–4pm, 
midnight–2am, and 12pm–2pm (see Figure 3).
Weekdays between 12pm and 8pm showed the highest fatalities, 
while the lowest fatality was reported at weekends between 8am 
and 12pm.
Recent legislation   continued
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Figure 2: Number of fatalities by day of week, 2018–2019
Source: RSA (2020), Figure 4, p. 5
Note: 2018–2019 data are provisional and subject to change.
Road collision fatalities   continued
0
150
100
50
200
250
300
350
400
450
500
163
188 192
162
185
156
142 148
199
8
199
7
199
9
20
00 20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09 20
10
20
11
20
12
20
13
20
14 20
15
20
16
20
17*
20
18*
20
19*
Nu
m
be
r o
f f
at
al
iti
es
Figure 1: Number of fatalities by year, 1997–2019
 Source: RSA (2020), Figure 1, p. 1
* 2017–2019 data are provisional and subject to change.
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Figure 3: Number of fatalities by time of day, 2018–2019
Source: RSA (2020), Figure 5, p. 6
Note: 2018–2019 data are provisional and subject to change.
Road collision fatalities   continued
Where fatalities occurred
Fatalities in 2018 and 2019 were more likely to occur in rural 
areas. 
Fatalities by speed limit
The highest number of fatalities occurred within an 80 km/h 
speed limit followed by 100 km/h. A large percentage increase 
(45%), which occurred within the 80 km speed limit, was 
evident between 2018 and 2019. 
Age profile
Fatalities were reported in all age categories. The majority 
of individuals who died on Irish roads during this timeframe 
were aged over 66 years. Between 2018 and 2019, there was 
a substantial increase (56%) in deaths in individuals aged 
between 26 and 35 years, while a 21% increase was evident in 
individuals aged 66 years or over.
Road user type
Across this timeframe the majority of individuals that died 
were drivers. Between 2018 and 2019, the number of drivers 
that died increased by 45%. The overall fatality figures in 2019 
were slightly higher than 2018 figures; two more fatal collisions 
were evident, which resulted in a 4% increase in deaths (n=6). 
Fortunately, the number of pedestrian fatalities decreased by 
36% (n=15); however, there was a substantial increase in driver 
fatalities (45%, n=25).
Age profile by road user type
In 2019, drivers aged 66+ years (n=23), followed by those aged 
26–35 years (n=19), and aged 16–25 years (n=12) were more likely 
to die on Irish roads.
Conclusion
The findings in this report will be used to inform policies and 
practices with the overall aim of reducing road fatalities. The 
Minister for Transport, Tourism and Sport, Shane Ross TD, 
expressed deepest condolences to the families of those who 
died on Irish roads. He acknowledged that the only response 
was via ‘action not words’ and emphasised the importance of 
‘continuing to implement life saving measures contained in the 
Road Safety Strategy’.3
The Minister went on to say that:
As ordinary road users … we need to take greater 
responsibility for our actions …. we can do this by 
slowing down, not driving while impaired through 
drink, drugs or fatigue, by not driving while using a 
phone, by wearing a seatbelt and always sharing the 
road more carefully with pedestrians and cyclists.3
Ciara H Guiney
1 Road Safety Authority (RSA) (2020) Provisional review of fatal 
collisions: 1 January to 31 December 2019. Dublin: Road Safety 
Authority. Available online at:  
https://www.rsa.ie/Documents/Fatal%20Collision%20Stats/
Provisional_Reviews_of_Fatal_Collisions/RRD_Res_20191231_
RSAProvisionalReviewFatalities31December2019_03Jan2020.pdf
2 Road Safety Authority (RSA) (2020) Provisional review of fatal 
collisions: January to 31 December 2019. Dublin: Road Safety 
Authority. https://www.drugsandalcohol.ie/31513/
3 Road Safety Authority (2020) 4% rise in road deaths recorded in 
2019. Dublin: Road Safety Authority. Available online at:  
https://www.rsa.ie/ga-IE/Utility/Nuacht/2020/4-Rise-in-Road-
Deaths-Recorded-in-2019/
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Twenty-First 
Annual Service of 
Commemoration  
and Hope
The National Family Support Network (NFSN)1 is an autonomous 
self-help organisation that provides support to families and 
respects the experiences of families affected by substance 
misuse in a welcoming non-judgemental atmosphere. On 
Saturday, 1 February 2020, the NFSN held its 21st Annual 
Service of Commemoration and Hope in the Church of 
Our Lady of Lourdes, Sean MacDermott Street, Dublin. This 
spiritual, multidenominational service is held in remembrance 
of loved ones lost to substance misuse and related causes 
and to publicly support and offer hope to families living with 
the devastation that substance misuse causes. Those in 
attendance included Ms Catherine Byrne TD, Minister of State 
at the Department of Health with responsibility for Health 
Promotion and the National Drugs Strategy; Comdt Caroline 
Burke, aide-de-camp to An Taoiseach; Mary Lou McDonald TD; 
Archbishop of Dublin Dr Diarmuid Martin, and other religious 
representatives; as well as family members, friends, and many 
people working in the area of substance misuse. Music was 
provided by soprano Nickola Hendy and Cathal Holland.
Work of the NFSN
In her address to the gathering, Sadie Grace, coordinator of the 
NFSN, spoke directly to family members in attendance, who are 
living with the effects of drug abuse on a daily basis. She stated 
that the NFSN stand in solidarity with them, stressing that they 
are not alone in their grief. 
While acknowledging more work is required to help prevent 
drug-related deaths and to support families affected by drug 
use, she highlighted the NFSN’s many achievements, including 
advocating strongly for accurate figures on drug-related deaths, 
which had culminated in the establishment of the National 
Drug-Related Deaths Index (NDRDI) in 2005; development 
of initiatives to address drug intimidation; setting up the first 
addiction-specific bereavement support counselling service; 
supporting research into the impact of familial addiction and 
drug-related deaths on the health of family members affected; 
advocating for the rollout of the naloxone programme, which was 
set up to help reverse the effects of opioid overdose through 
training, in recognition and response to overdose due to opioids, 
in addition to appropriate administration of naloxone. 
She acknowledged the assistance given by Archbishop Martin in 
helping the NFSN support families financially with funeral costs. 
Closing her address, Sadie urged family members to look after 
themselves, to avail of support, and to acknowledge that they 
deserve to be supported.
Impact of drug misuse and drug-related deaths
In her address, Minister Byrne emphasised the ongoing valuable 
work of the NFSN. She highlighted the recognition of family 
members as service users in their own right and the health-
led approach and actions on family support included in the 
current strategy.2 She extended her sympathy to the bereaved 
families present and acknowledged that families need services 
and support to help copy with drug-related issues, including 
specialised bereavement support but also in dealing with drug-
related intimidation and violence.
A testimony by a family member who has found support from 
the NFSN, highlighted the need for family members to look after 
their own health. Through engagement with a family support 
group as a mother, she learnt the importance of self-care, in a 
non-judgemental, comfortable environment, and that she was 
not alone in her struggles.
In his address, Archbishop Martin acknowledged the sadness, 
hope, courage, and solidarity among the gathering and spoke of 
the lack of respect for life within the drug trade, with children 
becoming entrapped in the world of drugs by heartless drug 
lords. 
Art competition
This year the NFSN held an art competition with the theme ‘Our 
Future’ for youth groups within the local and regional drug and 
alcohol task force areas. The theme of hope was very evident 
in the entries on display. First prize of €500 went to Kilbarrack 
Coast Community Programme; second prize of €300 went to 
Kilrush Youthreach; and third prize of €200 went to Dolphin 
House homework club.
For many families, this service was the first time that they could 
openly grieve for loved ones lost to drug use and related causes. 
Of note, the first commemoration service, 21 years ago, included 
one family support group based outside of the Dublin area. This 
year support groups from across Ireland were represented, 
a stark reminder that drug-related deaths affect families 
throughout the whole of Ireland. 
Ena Lynn
1 The National Family Support Network can be contacted at 5 
Gardiner Row, Dublin 1 on 01 898 0148 or info@fsn.ie or online 
www.fsn.ie 
 2 Department of Health (2017) Reducing harm, supporting recovery:  
a health-led response to drug and alcohol use in Ireland 2017-
2025. Dublin: Department of Health.  
https://www.drugsandalcohol.ie/27603/ 
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Action plan for 
drug use and higher 
education institutions
In June 2019, the Minister of State for Higher Education, Mary 
Mitchell O’Connor TD, convened a meeting of stakeholders to 
review the issue of drug use in higher education. Part of the 
outcome from this meeting was the establishment of a Rapid 
Response Group (RRG) whose brief was to develop an action 
plan on the issue, consistent with national strategy. In February 
2020, the Department of Education published the Framework 
for response to the use of illicit substances within higher 
education, which is based on the work of the RRG.1, 2
RRG membership
Membership of RRG included academics, members of An 
Garda Síochána, students, and first responders within higher 
education institutions (HEIs). It was chaired by Dr Andrew Power 
of the Institute of Art, Design and Technology (IADT) and led by 
Dr Michael Byrne, head of the Student Health Department at 
University College Cork (UCC). In her foreword to the report, 
the Minister described HEIs as having a role in implementing 
actions that can ‘reduce the number of students who decide to 
use drugs in the first place, or to reduce the harm experienced 
by those students who have chosen to use drugs’ (p. 3).1
Recommended actions
Central to the RRG’s report and subsequent framework is 
a set of actions that HEIs are recommended to undertake, 
where relevant to their institution. These are grounded in 
consideration of the following:
• Existing legislation regarding the use and misuse of drugs
• The National Drugs and Alcohol Strategy 2017–20253
• The evolving National Healthy Campus Charter and 
Framework
• Existing activities being carried out in HEIs to address drug 
and alcohol-related harm, including REACT (Reacting to 
Excessive Alcohol Consumption in Third-level)
• Input and expertise of RRG members.
The RRG identifies four core actions, with a further set of 12 
actions. The core actions recommend that each HEI should:
• Develop a drug and alcohol policy specific to the institution.
• Develop and implement a drug and alcohol action plan 
specific to the institution and its students.
• Assign to a senior officer of the institution the responsibility 
for leading the development of the policy and 
implementation of the action plan.
• Facilitate student engagement with the collection of 
national-level data on drug use in HEIs.
The additional 12 actions are divided under four themes: 
institutional leadership; student engagement; community 
engagement; and service provision.
Institutional leadership
This theme is focused on each HEI’s ability to adapt in a complex 
societal, academic, legislative, and policy environment, while 
also focusing on the ambitions and welfare of its students. In this 
context, the actions relate to the evaluation of the effectiveness 
of individual HEI action plans; the provision of designated 
substance-free student accommodation and social spaces; and 
the provision of space for support groups working with those 
experiencing problematic drug and alcohol use.
Student engagement
The actions under this theme recommend the provision of 
an online educational, screening, and brief intervention tool; 
consideration of substance use when planning large-scale 
student events; and the implementation of a student community 
support system.
Community engagement
In a context where HEIs consider themselves to have an 
important role to play in their local communities, the actions 
are to hold annual meetings with local stakeholders, such as 
local residents, Gardaí, and local businesses; and to develop 
partnerships with local community groups such as the local 
authority and local drug and alcohol task forces.
Service provision
The RRG notes the role of HEIs in providing adequate resources 
and services to meet the needs of their students. In line with 
this, the drug-related services identified in the actions are 
counselling services; visible and accessible referral pathways 
to treatment; interventions for higher risk groups described as 
‘vulnerable individuals or individuals from minority groups or 
communities’ (p. 15)2; and the provision of training for staff and 
students in order to deliver brief interventions and advice.
Drug Use in Higher Education in Ireland survey
In its report, the RRG identified a gap in knowledge about the 
extent and nature of drug use among students in HEIs. The 
Drug Use in Higher Education in Ireland (DUHEI) survey has 
been commissioned and is currently being conducted by a 
team based in the School of Public Health at UCC. It involves a 
multidisciplinary team of academics, researchers, and clinicians 
from Public Health, Business Information Systems, Psychology, 
and the Student Health Service in UCC, in collaboration with the 
Higher Education Authority and the RRG.
The survey aims to provide a comprehensive picture of drug use 
among the higher education population in Ireland. It will cover 
six areas:
• Demographics – age, gender, year of study, etc.
• Student life – club/society membership
• Drug use – lifetime, recent and current use, frequency of use 
and drug types, harms, and experiences of consequences
• Cognitive enhancers – use and motivations for use of 
cognitive enhancers
• Student wellbeing – personal and relationships
• Drug use social norms – student perceptions of drug use.
Fieldwork was due to be carried out in 22 HEIs across the 
country in March 2020 and a preliminary report presented to the 
Minister and all participating institutions in mid-2020 (personal 
correspondence, DUHEI Survey Team, UCC). However, due to the 
Covid-19 crisis the survey has been suspended.4
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Lucy Dillon
1 Rapid Response Group on Use of Illicit Substances within Higher 
Education (2020) Framework for response to the use of illicit 
substances within higher education. Based on the report of the 
Rapid Response Group (RRG) on Use of Illicit Substances within 
Higher Education. Dublin: Department of Education and Skills. 
https://www.drugsandalcohol.ie/31649/
2 Rapid Response Group on Use of Illicit Substances within Higher 
Education (2019) The report of the Rapid Response Group (RRG) 
on Use of Illicit Substances within Higher Education. Dublin: 
Department of Education and Skills.  
https://www.drugsandalcohol.ie/31649/
3 Department of Health (2017) Reducing harm, supporting recovery: 
a health-led response to drug and alcohol use in Ireland 
2017–2025. Dublin: Department of Health.  
https://www.drugsandalcohol.ie/27603/
4 See https://www.ucc.ie/en/studentsurveys/survey-calendar/
Know the Score
Know the Score is a new Government resource for Senior 
Cycle teachers to support their delivery of the substance use 
module of the Social, Personal and Health Education (SPHE) 
programme.1 By supporting teachers, the resource aims 
to guide and support students (aged 15–18 years) to ‘make 
conscious and informed decisions about alcohol and drugs’ (p. 
4).1 This complements the Health Service Executive (HSE) guide 
for parents on how to communicate with their children about 
alcohol and drugs published in August 2018.2 The resource was 
launched by Minister for Health Simon Harris TD, Minister for 
Education and Skills Joe McHugh TD, and Minister of State for 
Health Promotion and the National Drugs Strategy Catherine 
Byrne TD on 27 November 2019. 
Social, Personal and Health Education
SPHE sets out to provide students with dedicated time to 
‘further develop knowledge and understanding, values and 
attitudes and the life skills they need to live healthy lives and to 
contribute positively to the health and wellbeing of others and 
their communities’ (p. 7).3 Unlike in primary schools and the 
Junior Cycle in post-primary schools, SPHE is not a mandatory 
part of the curriculum for Senior Cycle.
Developing the resource
Know the Score is the outcome of a collaboration between the 
HSE Alcohol Programme and HSE Addiction Services, which was 
overseen by a Steering Committee made up of representatives 
from the HSE, the Professional Development Service for 
Teachers, and the Drug and Alcohol Task Forces. The resource 
content was also piloted by teachers and students in 10 schools.
Resource content
The objectives of Know the Score are aligned with those of the 
Curriculum Framework for the substance misuse module of 
SPHE (see Box 1). The wide range of objectives is reflected in 
the resource’s content. It is structured around 14 lesson plans 
and three short videos, and uses experiential and interactive 
teaching methodologies.1,4 Each lesson plan comes with a set of 
learning outcomes and resources for the teachers to draw upon 
in their delivery. Broadly speaking, Know the Score sets out to 
teach accurate information about drugs and related issues, as 
well as developing the skills necessary to make healthy choices 
and minimise the risk associated with substance use.
The resource includes relevant factual information, guides for 
class discussions, worksheets, and other activities. Based on an 
examination of the 14 sets of learning outcomes, some of the 
topics included are:
• Factual information about the range of drugs (both legal 
and illegal) and their effect on the user’s body and brain, as 
well as their physical and mental wellbeing
• Prevalence of substance use among young Irish people
• Students’ values, attitudes, and feelings in relation to 
substance use
• Assertiveness and communication skills in the context of 
substance use
• Positive strategies for dealing with stress as an alternative to 
substance use and personal skills to enhance confidence
• Low-risk drinking guidelines and methods for monitoring 
alcohol intake
• Awareness building of cultural attitudes towards alcohol 
in Ireland and the influence of alcohol brands and their 
advertising and sponsorship activities
• Skills development to deal with an emergency situation 
caused by substance misuse
• An understanding of cannabis, its legal status, and the 
myths and realities associated with its use.
As mentioned above, Know the Score also includes supporting 
digital content – three short videos – which aims to facilitate 
informed discussions about alcohol and drugs in the classroom. 
The topics covered are: drugs, the brain and dependency; 
cannabis; and risks of adolescent substance use.
Monitoring delivery
As with all SPHE modules at Senior Cycle, only pupils whose 
schools choose to deliver the substance misuse module will 
have the opportunity to benefit from the Know the Score 
resource. For schools that choose to deliver the module, it 
will require a teacher with the capacity and ability to deliver 
on the potentially sensitive content and the experiential and 
interactive teaching methodologies. A programme of one-day 
training sessions on Know the Score is underway and open to 
teachers nationally.5 At the time of writing, there are no plans in 
place to evaluate the resource and its delivery. 
Higher education institutions   
continued
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Lucy Dillon
1 HSE Alcohol Programme (2019) Know the Score: substance use 
resource materials for Senior Cycle SPHE. Dublin: Health Service 
Executive. https://www.drugsandalcohol.ie/31359/
2 Health Service Executive Alcohol Programme (2018) Alcohol and 
drugs: a parent’s guide. Practical advice to help you communicate 
with your child about alcohol and other drugs. Dublin: Health 
Service Executive. This guide was published in August 2018 and 
complements the students’ resource.  
https://www.drugsandalcohol.ie/29435/
3 National Council for Curriculum and Assessment (NCCA) (2011) 
Social, Personal and Health Education: Curriculum Framework. 
Senior Cycle. Dublin: NCCA. Available online at:  
https://www.ncca.ie/media/2688/sphe_framework.pdf
4 Links to the videos can be found at:  
https://www.drugsandalcohol.ie/31359/
5 A training programme for teachers commenced in January 
2020 and the Department of Education and Skills has provided 
substitution cover for this teacher training. Schools interested in 
attending the training or viewing a copy of the resource can visit: 
www.hse.ie/knowthescore
Know the Score   continued
Silent Voices – 
manifesto on parental 
alcohol misuse
Silent Voices is an initiative of Alcohol Action Ireland (AAI). As 
Ireland’s national charity for alcohol-related issues, AAI works 
in the areas of advocacy and policy change, aiming to reduce 
levels of alcohol harm in Ireland and improve public health, 
safety, and wellbeing. Silent Voices is focused on the impact of 
parental alcohol misuse (PAM) on children. It aims to ensure the 
right supports are available today to children coping with PAM – 
and those adults dealing with the impact of a childhood trauma 
in later life.1
Vision and mission
• Vision: Its vision is of a society where no person impacted 
by PAM will be left unsupported.
• Mission: It works to achieve this vision by destigmatising the 
experience of growing up with PAM in Ireland; by increasing 
a better understanding of the adverse impact of this 
experience on emotional and mental health; and by working 
to enhance supports to those who have lived or are now 
living with PAM.
Silent Voices activities
There are three broad areas of activities outlined for Silent 
Voices:
1 Raise awareness of the impact of PAM through advocacy, 
education, and information. Tools used include personal 
testimony; sharing experiences; and signposting and listing 
resources.
2 Facilitate a better understanding of PAM by providing 
information and insight to the following groups: health 
professionals and practitioners; media; parents; 
policymakers; people who have contact with children;  
and volunteers.
3 Enhance services for children and adult children of PAM by 
working in partnership to initiate, develop, or contribute 
to research; fundraising; and development of online 
information and literature supports.
Manifesto
The Silent Voices manifesto was published in advance of 
General Election 2020.2 In addition to outlining the research 
and policy context for the Silent Voices initiative, it contains 
a set of 13 recommendations across three areas: a whole-
Government approach to the issue; services and supports; 
and training and awareness raising. The recommendations 
are aimed at Government and set out to address the harm 
caused by PAM and its impact across the lifespan. Among the 
recommendations are:
• A designated senior Government official should be 
appointed with responsibility for advising, developing, 
and planning appropriate policies and services to meet 
Objectives of Know the Score
The objectives of the Know the Score resource are the 
same as those outlined in the substance use area of learning 
in the Curriculum Framework for SPHE in Senior Cycle  
(p. 8):1
• To enhance students’ knowledge and understanding 
about substance use and misuse
• To develop awareness of personal experiences, values, 
attitudes, and feelings which influence lifestyle choices 
about substance use
• To develop students’ personal and interpersonal skills so 
that they might have the confidence to act appropriately 
in the face of social pressures, and to choose how they 
act with awareness
• To examine life stories associated with the harmful use of 
substances to develop understanding and empathy with 
those involved
• To examine the external influences on substance use, 
including the media, peers, and community
• To remind students that deciding not to drink or use 
drugs is always a legitimate choice
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the needs of those who experience harm caused by PAM, 
and should have the capacity to work across Government 
Departments.
• Because educators are well placed to identify children 
experiencing hidden harm, the provision of specific training 
in relation to adverse childhood experiences should be 
examined at teacher training level and at all levels of 
professional development – from teachers to principals to 
education welfare officers.
• In addition to existing services, properly funded and 
resourced supports should be developed for children 
experiencing PAM. Innovative evidence-based programmes 
should become more widely available in communities 
around the country. It should also be ensured that children, 
as an individual right, can access services, even where 
parents are not in treatment.
• Awareness of PAM and its impact on young and adult 
children should be raised through information campaigns 
and training that target healthcare, social care, early years, 
child protection, family support, education, and mental 
health sectors, as well as families and communities. Such 
campaigns should also reach an adult cohort who perhaps 
has yet to recognise the underlying cause of its own 
problems.
• Data should be gathered on the lives of children and adult 
children who have experienced PAM in Ireland to inform 
policy development and service provision.
• Public discourse/debate on the right to a childhood free 
from alcohol harm should take place and children should 
have their voices heard in relation to the impact of alcohol 
on their lives.
Lucy Dillon
1 For further information, visit:  
http://alcoholireland.ie/campaigns/silent-voices/
2 Alcohol Action Ireland (2019) Silent Voices manifesto. Dublin: 
Alcohol Action Ireland. https://www.drugsandalcohol.ie/31465/
Oral fluid testing 
for methadone 
maintenance patients 
– accuracy and 
acceptability
Methadone maintenance treatment is an addiction treatment 
provided to about 10,000 people in Ireland to improve their 
health and stability.1 In a 2019 study published in the Irish 
Journal of Medical Science, O’Callaghan et al.2 investigated 
how accurate and acceptable oral fluid testing is to 
methadone maintenance patients and doctors as a means of 
substance detection. Importantly, this was the first Irish study 
capturing patient views on their experience with methadone 
maintenance.
Background
According to the authors, drug testing during methadone 
maintenance is crucial as it provides doctors with important 
insights into patient stability and contributes to decisions 
about the level, frequency, and supervision of methadone 
delivery. In Ireland, unsupervised urine testing is commonly 
used and preferred by general practitioners (GPs). However, 
unsupervised urine samples can be subject to falsification, and 
the 2010 external review of the Irish Methadone Maintenance 
Treatment Protocol3 called for discontinuing supervised 
urine testing due to its inherent infringement of patient 
privacy. Testing oral fluid rather than urine is an alternative 
method for detecting drug metabolites under supervision, 
without compromising patient privacy. However, its window 
of detection is shorter than that of urine testing. Hence, the 
current study examined how accurately oral fluid testing could 
detect drug metabolites in comparison with urine testing and 
self-report. It also investigated patients’ and doctors’ views 
on the acceptability of each method and on methadone 
maintenance generally.
Methods
The study was carried out with seven GPs from four practices 
within the GP training scheme of Trinity College Dublin and the 
Health Service Executive from January to April 2016. Of the 65 
invited patients, 55 (85%) agreed to participate. The average 
age of participants was 42.5 years and about two-thirds were 
male. The authors compared how many patients in the sample 
(n=55) were identified as having consumed a substance by 
means of (a) unsupervised urine testing, (b) supervised oral fluid 
testing, and (c) self-report. Patient views were captured with an 
eight-item questionnaire administered by GPs.
Key findings
Accuracy
For most drugs, results from oral fluid testing were similar to 
those from urine testing, with the exception of benzodiazepines 
(see Figure 1).
• Methadone: Consumption of methadone was confirmed 
through all three methods for all patients (n=55).
• Benzodiazepines: Detection of benzodiazepines was 
superior in urine testing (n=41) and self-report (n=37) 
compared with oral fluid testing (n=18).
• Opiates: Detection of opiates was highest by means of self-
report (n=16), and much lower both through urine (n=3) and 
oral fluid testing (n=5). Additionally, only self-report could 
identify the type of opiate (heroin n=3; painkillers n=13).
• Cocaine and amphetamines: Self-report was superior in 
capturing cocaine consumption (n=6) compared with both 
urine (n=2) and oral fluid testing (n=1). Only one patient self-
identified as having consumed amphetamines, which was 
picked up by neither urine nor oral fluid testing.
Silent Voices   continued
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Figure 1: Drug testing results by each of the three methods (n=55)
Acceptability
• Views: Most patients (95%) and the seven participating 
GPs evaluated oral fluid testing as acceptable and 
straightforward, with 60% of patients preferring oral fluid 
testing, but 13% preferring urine testing.
• Time and reliability: GPs noted that additional time was 
necessary to perform both tests; three of them stressed 
the lack of reliability in the detection of benzodiazepines 
through oral fluid testing.
• Urine sample supervision: Contrary to author 
expectations, only 15% of patients were against supervised 
urine samples. The authors attributed this to potential 
reluctance among patients to express negative views to 
their doctors directly, as well as possible altered levels of 
self-esteem and expectations for privacy for methadone 
patients.
Patient experience of methadone maintenance
• Positive vs negative views: Overall, negative views of 
methadone maintenance were more frequent than positive 
ones among the patient sample.
• Detoxification: More options for detoxing off methadone 
were desired by 20% of patients.
• Positive perceptions: Perceived positive aspects included 
methadone allowing for stabilisation (28%), an alternative to 
drug use (25%), and better functioning (18%).
• Negative perceptions: Perceived negative aspects included 
methadone being addictive (30%), associated with stigma 
(12%), a long-term treatment (11%), causing dental issues 
(11%), and causing physical side-effects (10%).
Discussion and conclusions
The current study found that, for most drugs, results from 
oral fluid testing were similar to those from urine testing but 
inferior for benzodiazepines. O’Callaghan et al. attributed this 
to the longer window of detection of benzodiazepines in urine 
compared with oral fluid. However, while many participants 
reported using benzodiazepines (67%), the authors state 
that 61% had a prescription for them, drawing into question 
the importance of their detectability. Hence, the authors 
conclude that oral fluid testing is an acceptable addition for 
drug screening in methadone maintenance treatment, and 
especially advantageous if a urine sample cannot be supplied. 
Additionally, they found that self-report as a measure of 
concomitant drug use was as or more worthwhile compared 
with urine or saliva testing.
However, the authors suggest that studies with larger samples 
are necessary to further investigate the detectability of drugs 
through oral fluid testing, especially when considering the low 
number of patients recorded as having consumed cocaine 
and amphetamines (through self-report or testing). Overall, 
given the increasing drug-related mortality observed in Ireland, 
the authors stress the importance of more research on the 
substance use but also the perspectives and experiences of 
methadone maintenance patients.
Britta Thiemt
1 Delargy I, Crowley D and Van Hout MC (2019) Twenty years of the 
methadone treatment protocol in Ireland: reflections on the role 
of general practice. Harm Reduct J, 16(1): 5.  
https://www.drugsandalcohol.ie/30173/
2 O’Callaghan ME, Regan L, Wilson M, Byrne E, Hollywood B, O’Kelly 
F, et al. (2020) Acceptability and accuracy of oral fluid drug 
testing for patients on methadone maintenance. Ir J Med Sci, 189: 
557–561. https://www.drugsandalcohol.ie/31236/
3 Farrell M and Barry J (2010) The introduction of the opioid 
treatment protocol. Dublin: Health Service Executive.  
https://www.drugsandalcohol.ie/14458/
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prescribing of 
pregabalin
In January 2020, the Medicines Management Programme in the 
Health Service Executive published a document on appropriate 
prescribing of pregabalin (common brand name Lyrica).1 It 
advises that vigilance is required when prescribing pregabalin 
due to the risk of dependence, illegal diversion, and medical 
misuse. Currently pregabalin has only three licensed indications 
in Ireland:
• Treatment of peripheral and central neuropathic pain
• Treatment of generalised anxiety disorder
• Adjunctive therapy in patients with partial seizures with or 
without secondary generalisation.
This follows on from advice provided by the Irish Medical 
Council in September 2019 to doctors when prescribing 
pregabalin to follow best practice guidelines and to only 
prescribe when absolutely necessary.2
Because of the risk of misuse or dependence, caution is 
advised when prescribing pregabalin for people with a history 
of drug or alcohol misuse, particularly as there is a risk of 
fatal interactions between pregabalin and alcohol in addition 
to other central nervous system depressant drugs, including 
opioids. All patients should be monitored for signs of misuse, 
diversion, or dependence. Withdrawal symptoms include 
anxiety, convulsions, depression, diarrhoea, dizziness, flu 
syndrome, headache, excessive sweating, insomnia, nausea, 
nervousness, and pain. The suggested tapering regime is to 
reduce the dose gradually by a maximum of 50–100 mg.
Suzi Lyons
1 Medicines Management Programme (2020) Appropriate 
prescribing of pregabalin. Dublin: Health Service Executive. 
Available online at:  
https://www.hse.ie/eng/about/who/cspd/ncps/medicines-
management/prescribing-tips-and-tools/appropriate-
prescribing-of-pregabalin-.pdf
2 Medical Council (2019) Medical Council warns doctors to reduce 
over-prescribing of benzodiazepines, Z-drugs and pregabalin or 
face potential investigation (September 2019). Dublin: Medical 
Council. Available online at:  
https://www.medicalcouncil.ie/news-and-publications/press-
releases/press-release/items/medical-council-warns-doctors-
to-reduce-over-prescribing-of-benzodiazepines.html
Risk of drug-related 
poisoning deaths and 
all-cause mortality 
among people who 
use methadone
Methadone is the most commonly prescribed opioid 
substitution treatment in Ireland. A retrospective cohort study 
was carried out in all specialist addiction services in Dublin 
South West and Kildare looking at the risk of death associated 
with interruptions in methadone maintenance treatment (MMT) 
for the years 2010–2015.1
Methods
Using data from the Central Treatment List and the Health 
Service Executive Methadone Treatment Scheme, start and 
end dates for patient MMT were identified from methadone 
dispensing data. This information was then linked to mortality 
data from the National Drug-Related Deaths Index (NDRDI) 
and prescription data from the General Medical Services. The 
researchers were therefore able to categorise the treatment 
status for every day for each patient (addiction services, 
primary care, prison, out of treatment). ‘In treatment’ was 
defined as a continuous daily supply of methadone. If a patient 
did not receive a new prescription within 7 days after the 
end of the last prescription, they were considered to be ‘off 
treatment’. The patient remained off treatment until they 
received a new prescription.
There were five groups within the study: weeks 1–4 following 
transfer between treatment providers; weeks 1–4 out of 
treatment; weeks 5–52 out of treatment; weeks 1–4 of 
treatment initiation; and weeks 5+ of continuous treatment. 
A drug-related poisoning (DRP) death was classified as the 
primary outcome measure, while an all-cause mortality (ACM) 
death was classified as the secondary outcome.
Findings
The study included 2,899 patients over the six-year study 
period, equating to 13,300 person-years. The median follow-
up period was 5.5 years. The majority were male (63.3%), with 
a median age of 33.9 years. Forty-nine per cent (48.5%) of 
patients were found to have transferred, on average, three 
times between services. Most of the transfers were back and 
forth between prison and addiction services. Many patients 
included in the study had evidence of physical ill-health and/
or mental health problems, with 66.9% reporting two additional 
problems, most commonly mental health problems (66%), 
diseases of the digestive system (34%), and diseases of the 
respiratory system (24%). The study also recorded the median 
methadone dose at the last treatment episode, as follows:
• 40.5% median dose <60 mg
• 56.1% median dose 60–120 mg
• 3.4% median dose ≥120 mg.
Of the 2,899 patients included, 154 (5.3%) were known to have 
died. There were no deaths recorded in weeks 1–4 following 
transfer between treatment providers. Of those who died, one-
third (n=55, 36.2%) were a DRP (crude DRP mortality rate of 
0.41 per 100 person-years [95% CI: 0.30–0.52]). After adjusting 
the analysis for other factors, the risk of DRP was highest 
in weeks 1–4 out of treatment and weeks 1–4 of treatment 
initiation (see Table 1). The risk was higher for women and 
increasing age. The crude ACM was higher than DRP, with a rate 
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of 1.14 per 100 person-years [95% CI: 0.96–1.32]. As with DRP, 
the risk of ACM was highest in weeks 1–4 out of treatment and 
weeks 1–4 of treatment initiation (see Table 1). The risk of ACM 
was higher for those with a recorded disease of the circulatory 
system and increasing age, while the risk was reduced for those 
with a history of imprisonment.
The authors noted that the 7-day rule used to categorise 
treatment status could be a bias in the study, as some patients 
may not have stopped treatment. Therefore, they conducted 
the analysis using 14 days instead of 7 days. This did not change 
the results, with the exception that the risk of ACM for weeks 
1–4 in treatment did not remain significant in the multivariate 
analysis.
The strength of the study is that it included a large number 
of patients, representing almost one-half of all those in MMT 
treatment during that time. There was a long follow-up time 
and the study utilised a number of existing databases to 
account for interruptions to treatment and mortality.
Limitations
A number of weaknesses and biases were acknowledged. 
There were other factors and confounders associated with 
interruption of treatment that could not be accounted or 
controlled for. One example cited was where a patient may 
have left treatment, moved into recovery and had stopped 
problem opioid use, and had therefore reduced their risk of 
mortality compared with those who relapsed and returned 
to treatment. The researchers used a 12-month limit for 
follow-up after stopping treatment to control for this potential 
confounder. The study did not include transfers to/from 
hospital, as hospitals are not required to report to the Central 
Treatment List. Therefore, given the high proportion of patients 
who also suffered from physical illnesses, it may be that those 
off treatment had been admitted to hospital for treatment 
for those illnesses, which might have influenced the results. 
Patients on Suboxone were also not included in the study.
Conclusions
This study confirms that the first 4 weeks after treatment 
initiation and after stopping treatment have the highest risk for 
mortality among patients in MMT in Ireland. While this trend 
is similar to findings from United Kingdom studies, mortality 
rates observed in this study were higher. This may be due to 
ageing among problem opioid users along with higher levels of 
comorbidity. The increased risk at initiation could be attributed 
to continued use of illicit opioids or other respiratory 
depressant drugs, or could be tolerance related. There were 
no deaths recorded in the first 4 weeks after transfer between 
services. Given that many of those transfers were to and from 
prison, this may reflect the policy of keeping a person’s place in 
community MMT until they are released from prison.
Risk of drug-related poisoning   
continued
Interruptions to MMT continuity Adjusted relative risk 95% CI
DRP mortality rate per 100 person-years
Weeks 1–4 following transfer between treatment providers 0.00 - -
Weeks 1–4 out of treatment 1.29 4.04 1.43–11.43
Weeks 5–52 out of treatment 0.27 1.00 0.03–3.34
Weeks 1–4 of treatment initiation 1.11 3.40 1.20–9.64
Weeks 5+ of continuous treatment 0.39 1.00 –
ACM mortality rate per 100 person-years
Weeks 1–4 following transfer between treatment providers 0.00 - -
Weeks 1–4 out of treatment 9.32 11.78 7.73–17.94
Weeks 5–52 out of treatment 1.43 2.04 1.20–3.47
Weeks 1–4 of treatment initiation 4.17 5.11 2.95–8.83
Weeks 5+ of continuous treatment 0.82 1.00 –
Table 1: DRP and ACM mortality rates per person-years and adjusted relative risk by interruptions to MMT continuity
Source: Durand et al. (2020)
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The authors recommend further investigation into the risks for 
patients caused by transfer between services. Seeing that the 
study shows the greatest risk of mortality at treatment initiation 
or after treatment stops, the authors also recommend closer 
monitoring of opioid tolerance at these times as well as relapse 
prevention strategies, which would include provision of take-
home naloxone.
Suzi Lyons
1 Durand L, O’Driscoll D, Boland F, Keenan E, Ryan B, Barry J, 
et al. (2020) Do interruptions in the continuity of methadone 
maintenance treatment in special addiction settings increase the 
risk of drug-related poisoning deaths? A retrospective-cohort 
study. Addiction, Early online. https://www.drugsandalcohol.
ie/31615/
Building community 
resilience: response 
to criminal networks 
in Dublin
In December 2019, Four Forum Network (4Fora) and Dublin 
City Council published a report, Building community resilience: 
responding to criminal and anti-social behaviour networks 
across Dublin South Central.1 4Fora comprises four local 
policing fora in the Dublin South Central area, and the report  
was carried out in collaboration with An Garda Síochána. 
Research aims
The research aimed to explore five areas:
1 Nature and spread of criminal and antisocial behaviour 
(ASB) networks.
2 Impact of these networks on people residing in Dublin 
South Central.
3 Relationships between socioeconomic indicators and the 
operation and impact of networks, including circumstances 
that enabled resilience.
4 Mapping and evaluation of existing initiatives, structures, 
and resources.
5 Requirements necessary to address impact and causes of 
these networks.
Methodology
To address the research aims, several approaches were utilised 
to gather data:
• Social network analysis
• Interviews with Garda members using Twinsight 
methodology, developed in the Greentown study2
• Socioeconomic analysis of network members
• Mapping of crime and ASB hotspots
• Attending local meetings
• Focus groups, involving community activists
• Research ethics.
Findings
Nature and reach of criminal/ASB networks in Dublin 
South Central
Approximately 650 people were involved in the overall network, 
which could be stripped down to two distinct networks: Dublin 
South Central Network One (SCN1), consisting of 44 people, 
and Dublin South Central Network Two (SCN2), consisting of 52 
people. Some of these network members committed crimes on 
at least one occasion between 2015 and 2016.
Impact of criminal networks on residents
Perceptions of the impact of criminal networks were provided 
by Garda respondents and local community activists. Similar 
to existing research findings in this area, the impact of criminal 
networks was considered to be hidden. Several themes 
emerged; for example, issues were identified in schools as a 
result of being associated with different networks. Drug debt 
was considered a route to engagement with networks and 
criminal behaviour, as were fear and easy access to money 
and material goods for young people. Lack of opportunities 
for young people also pushed them towards criminal network 
opportunities.
Community activist perspectives
The link between the frequency of criminal activity and 
economic deprivation has long been the focus of criminological 
research. In this study, according to the Pobal HP Deprivation 
Index map, the majority of members in SCN1 and SCN2 ranged 
from marginally below average to very disadvantaged, 86% and 
88%, respectively.
Building resilience was viewed as a way to help communities 
provide community-based resolutions to tackle criminal 
networks and crime. Failure to consistently reinforce pro-social 
behaviour was cited by Garda respondents as an issue. It was 
acknowledged that some communities were able to ‘take a 
stand’ (p. 62) against ASB, however, other communities were 
not.
Initiatives, structures, and resources
An overview of current community safety structures, initiatives, 
and resources was provided. It was acknowledged by 4Fora that 
structures and functioning could be improved. Reluctance of 
communities to engage with Gardaí was highlighted. The issues 
dealt with across the structures were similar, such as lack of 
Garda resources; difficulties filling Garda vacancies; low Garda 
visibility; Garda response to calls on serious issues insufficient, 
in particular ASB in parks; criminal ‘hotspots’; intimidation; and 
gang-related feuding.
Risk of drug-related poisoning   
continued
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Care and control responses
Building a holistic approach to criminal issues in the community 
emerged as an area of importance. Involvement in community 
safety groups may have implications for personal safety; hence, 
residents are unwilling to participate. As a result, it falls to 
community-based workers to carry out this role. Two problems 
need to be considered: (a) keeping individuals who are willing 
to take part safe and (b) making sure that responses to criminal 
behaviour is not ‘enforcement oriented’ (p. 12), that is, responses 
are not about arresting individuals, carrying out surveillance, 
delivering warnings, and evictions. The authors acknowledged 
that while this was important, building resilience in communities 
needed a more subtle and viable approach.
Criminal networks in Dublin   
continued
Future guiding principles and action plan
The Building community resilience report can be viewed 
as a starting point for developing a strategy to address ASB 
and criminal behaviour in the Dublin South Central area. It 
identifies the main characteristics of the drug trade and ASB 
networks and elaborates on how it impacts on the community. 
The 4Fora have provided an outline strategy that identifies the 
vision, specific actions, and structural reforms necessary to 
implement it.
Ciara H Guiney
1 Connolly J and Mulcahy J (2019) Building community resilience: 
responding to criminal and anti-social behaviour networks across 
Dublin South Central – a research study. Dublin: Four Forum 
Network and Dublin City Council.  
https://www.drugsandalcohol.ie/31426/
2 Department of Children and Youth Affairs (2016) Lifting the lid on 
Greentown: why we should be concerned about the influence 
criminal networks have on children’s offending behaviour in 
Ireland. Dublin: Government Publications.  
https://www.drugsandalcohol.ie/26850/
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UPDATES
Recent publications
PREVALENCE AND CURRENT SITUATION
A national case fatality study of drugs taken in intentional 
overdose
Daly C, Griffin E, Corcoran P, et al. (2020) International Journal of 
Drug Policy, 76: 102609.
https://www.drugsandalcohol.ie/31526/ 
This study aimed to examine the incidence of intentional drug 
overdose (IDO), to identify the predictors of fatal IDO and to 
establish which drugs are linked with greater risk of a fatal 
outcome.
Male gender, increasing age and multiple drug use were associated 
with fatal IDO outcome. Tricyclic antidepressants and opioids were 
associated with a significantly increased risk of death following 
intentional overdose. Clinicians need to consider the case fatality 
risk of drugs when determining treatment for patients at risk of or 
those who have previously harmed themselves.
Counting the toll of smoking-attributable hospitalisations
Sheridan A, Quintyne KI and Kavanagh P (2020) Irish Medical 
Journal, 113(1): 8.
https://www.drugsandalcohol.ie/31554/ 
In Ireland, 20% of adults smoke. Many current and ex-smokers live 
with ill-health and disability as a result of smoking, and this study 
aimed to quantify the extent of smoking-related hospitalisations in 
Irish publicly funded hospitals.
Smoking continues to cause a considerable impact on hospital 
services in Ireland.
National Drugs Library
'Bursting the Lyrica bubble': experiences of pregabalin use in 
individuals accessing opioid agonist treatment in Dublin, Ireland 
Brennan R and Van Hout MC (2020) Heroin Addiction and Related 
Clinical Problems, Early online.
https://www.drugsandalcohol.ie/31533/ 
This study aims to add to the evidence based on diverted 
pregabalin use in the opioid agonist treatment (OAT) cohort in 
Ireland.
We report here on the first study in Ireland investigating the 
experiences of individuals who access opioid agonist treatment 
and reported current or recent pregabalin use. Increased 
pharmaco-vigilance amongst medical practitioners is warranted 
when prescribing Lyrica to individuals with vulnerabilities such as 
a history of problematic drug use. Trauma informed interventions 
in addition to pragmatic harm reduction information for polydrug 
users to prevent cross tolerance, dependence and overdose 
deaths should be part of the healthcare and policy response.
Treatment of adolescent heroin dependence: the end of an era
Smyth BP and McCarney G (2020) Irish Medical Journal, 113(1): 2.
https://www.drugsandalcohol.ie/31553/ 
[Editorial] In the 1990s, Ireland had the youngest population of 
heroin dependent patients in Europe. At that time problems were 
largely confined to Dublin, and within Dublin use was concentrated 
in specific areas of very significant deprivation. At the peak of 
the heroin epidemic in 1996, there were over 180 adolescents 
(under 18) presenting for addiction treatment in Dublin annually 
with a heroin use disorder. Given that addiction services had 
been developed with adults in mind, the National Drug Treatment 
Centre established the Young Persons Program (YPP) in 2000, in 
recognition of the very different needs of these young patients. 
The authors, both child and adolescent psychiatrists, arrived into 
the service a few years later.
A repeated cross-sectional study of factors associated with 
pregabalin-positive poisoning deaths in Ireland
Lynn E, Cousins G, Lyons S and Bennett KE (2019) Drug and Alcohol 
Dependence, 206: 107741.
https://www.drugsandalcohol.ie/31323/ 
In this study we examined factors associated with pregabalin-
positive poisoning deaths (PPPD) between 2013 and 2016 in Ireland.
Enhanced training to prescribers and treatment providers on 
the potential risks associated with pregabalin, particularly among 
people who use drugs, is required.
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Low levels of chemsex among men who have sex with men, but 
high levels of risk among men who engage in chemsex: analysis 
of a cross-sectional online survey across four countries
Frankis J, Flowers P, McDaid L and Bourne A (2018) Sexual Health, 
15(2): 144–150.
https://www.drugsandalcohol.ie/31315/ 
This paper establishes the prevalence of chemsex drug use among 
men who have sex with men (MSM), the extent to which these 
drugs are used in a sexual context, as well as their associated 
behaviours and circumstances of use.
Only a small proportion of MSM in Scotland, Wales, Northern 
Ireland and the Republic of Ireland reported chemsex, and, for 
the first time, it is demonstrated that not all chemsex drug use was 
sexualised. Nevertheless, MSM who engage in chemsex (MWEC) 
reported substantial sexual risk inequalities. These novel findings 
highlight several opportunities for intervention, particularly 
around the multiple vulnerabilities of MWEC, opportunities for 
early identification of those most vulnerable to chemsex-related 
harm and the potential to develop a specialised responsive patient 
pathway.
Prevention of suicidal behaviour: results of a controlled 
community-based intervention study in four European 
countries
Hegerl U, Maxwell M, Harris F, Koburger N, Mergl R, Székely A, et al. 
(2019) PLoS One, 14(11): e0224602.
https://www.drugsandalcohol.ie/31340/ 
This paper reports on the primary outcome of the intervention 
(the number of completed and attempted suicides combined 
as 'suicidal acts') and on results concerning process evaluation 
analysis. Interventions were implemented in four European cities 
in Germany, Hungary, Portugal and Ireland, with matched control 
sites.
Hypothesised mechanisms of action for successful 
implementation were observed and drivers for 'added-value' were 
identified: local partnership working and 'in-kind' contributions; 
an approach which valued existing partnership strengths; and 
synergies operating across intervention levels. It can be assumed 
that significant events during the implementation phase had a 
certain impact on the observed outcomes. However, this impact 
was, of course, not proven.
Electronic cigarette vapour increases virulence and 
inflammatory potential of respiratory pathogens
Gilpin DF, McGown KA, Gallagher K, et al. (2019) Respiratory 
Research, 20: 267.
https://www.drugsandalcohol.ie/31477/ 
This study compared the effect of e-cig vapour (ECV) and 
cigarette smoke (CSE) on the virulence and inflammatory potential 
of key lung pathogens (Haemophilus influenzae, Streptococcus 
pneumoniae, Staphylococcus aureus and Pseudomonas 
aeruginosa). 
The findings suggest that ECV and CSE can induce changes in 
phenotype and virulence of key lung pathogens, which may 
increase bacterial persistence and inflammatory potential.
Sponsorship, advertising and alcohol control in Ireland: the 
importance of both premises and products in regulating 
intoxigenic environments
Houghton F and McInerney D (2019) Irish Journal of Medical 
Science, Early online.
https://www.drugsandalcohol.ie/31423/ 
Ireland’s relationship with alcohol is decidedly problematic. Per 
capita alcohol consumption and binge drinking rates in Ireland 
are both worryingly high. Such excess results in significant costs 
in terms of morbidity, mortality, finances and valuable and finite 
health and hospital resources. Results from both the ESPAD 
[European Schools Project on Alcohol and Other Drugs] survey 
and the HBSC [Health Behaviour in School-Aged Children] survey 
therefore clearly indicate that youth initiation into alcohol use is 
a significant issue. Further validation of this issue may be seen in 
results from the National Alcohol Diary Study which indicated that 
almost two-thirds (63.9%) of males and half (51.4%) of females 
in Ireland started drinking alcohol before the age of 18 years. 
These findings are extremely important as evidence examining 
the impact of alcohol on the developing brain has identified 
the ‘disrupting effects of adolescent binge drinking on the 
developmental trajectories of both brain and personality'. 
Safer injecting facilities: will they work in an Irish context?
Bates C (2019) Irish Probation Journal, 16: 184–197.
https://www.drugsandalcohol.ie/31389/ 
This article considers the context and policy development in 
Ireland around the introduction of safer injecting facilities (SIFs), 
in addition to exploring the debates about their operation. The 
findings from a small-scale research study, conducted by the 
author as part of a master’s programme in criminology and 
criminal justice in University College Dublin in 2018, are outlined. 
The focus of this research was to gauge the views of members of 
An Garda Síochána (n = 5) based in the Dublin metropolitan area 
on the potential for SIFs to operate effectively and efficiently. 
Gardaí were identified as appropriate participants as they are 
often the first point of contact with street drug users and have an 
awareness of how the introduction of SIFs may impact on policing 
strategy and operations.
Reducing youth crime: the role of mentoring
O’Dwyer K (2019) Irish Probation Journal, 16: 153–167.
https://www.drugsandalcohol.ie/31390/ 
This article discusses the role of mentoring in reducing youth 
crime, drawing on a 2016 evaluation of Le Chéile mentoring 
services in the Republic of Ireland. There are many studies of 
mentoring of ‘at risk’ children and young people, which show a 
range of benefits when good practice is followed. There are fewer 
studies of mentoring of young offenders, and results are less 
clear-cut – variously described as ‘promising’, ‘mixed’, ‘indirect’, 
‘modest’, ‘tantalising’ or lacking clear evidence.
The article examines the reasons for the equivocation about 
mentoring outcomes in other jurisdictions and explores possible 
reasons for Le Chéile’s positive results. It discusses a number 
of themes, including the importance of volunteer mentors, the 
building of relationships of trust, the balance between listening 
and challenging, and the importance of commitment and 
perseverance. 
Recent publications   continued
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POLICY
Removing the last billboard for the tobacco industry: 
tobacco standardized packaging in Ireland
Crosbie E (2019) Health Policy, 123(10): 932–935.
https://www.drugsandalcohol.ie/31537/ 
Tobacco Free Ireland set out 60 recommendations and 
measures to reach the 2025 target, including introducing 
SP [standardized packaging]. Tobacco companies and 
trademark and intellectual property organizations opposed 
the SP proposal claiming it would: (1) not work to reduce 
smoking levels, (2) increase illicit tobacco trade, (3) create 
unnecessary problems for retailers, and (4) violate domestic 
and international laws governing trademarks. However leading 
health groups in Ireland presented evidence on how SP would 
communicate the harms of tobacco to smokers and discourage 
young people from beginning to smoke. These efforts combined 
with strong political will helped Ireland to become the second 
country in the world to enact standardized packaging for all 
tobacco products.
Reducing harm, supporting recovery: a partnership and 
evidence-informed approach to developing the new Irish 
health led, National Drug Strategy
Comiskey C (2020) Harm Reduction Journal, 17(1): 3.
https://www.drugsandalcohol.ie/31534/ 
Policy development by partnership is difficult, however, 
'Reducing Harm, Supporting Recovery: A health led response 
to drug and alcohol use in Ireland 2017-2025' hailed a new era. 
This policy was based on an agreed philosophy and core values 
across a 21-member partnership and has stated a common 
commitment to a health-led response.
A key recommendation from the process was to ensure that all 
voices had an equal opportunity to be heard and to ensure that 
priority actions identified from the wider sources of evidence 
were not lost during the extended process. The breadth of the 
partnership aided this. While we have succeeded in developing 
a sound strategy, success will depend on continuing support 
from the partnership and appropriate resourcing from the 
ministries.
A senior management perspective on the policy debate 
of needle and syringe exchange program provision in Irish 
prisons
Rosalim JP (2020) Journal of Correctional Health Care, 26(1): 
27–35.
https://www.drugsandalcohol.ie/31593/ 
This study examined from an Irish perspective the contentious 
policy debate about providing clean needles to injecting 
drug users within prison systems; specifically, it examined the 
views of six senior managers who were prison health staff and 
security management. 
Research participants were generally opposed to the 
introduction of prison-based needle and syringe exchange 
programs (PNSP) in Ireland. They argued that (1) PNSP were 
unnecessary since injecting drug use within Irish prisons 
has declined significantly, (2) PNSP, by making needles freely 
available to prisoners, would make prisons riskier since these 
needles might be used as weapons against prison staff or other 
prisoners, and (3) PNSP might be seen as condoning illicit drug 
use and sending the 'wrong message'. It is concluded that, for 
the moment at least, there is little likelihood of PNSP becoming 
a reality in the Irish Prison Service.
RESPONSES
Hepatitis C virus infection in Irish drug users and prisoners - 
a scoping review
Crowley D, Murtagh R, Cullen W, Lambert JS, McHugh T and Van 
Hout MC (2019) BMC Infectious Diseases, 19(1): 702.
https://www.drugsandalcohol.ie/31395/ 
The aim of this review was to map key findings and identify gaps 
in the literature (published and unpublished) on HCV [hepatitis 
C virus] infection in Irish PWUD [people who use drugs] and 
prisoners.
Ireland like other European countries has high levels of 
undiagnosed and untreated HCV infection. Collecting, 
synthesising and identifying gaps in the available literature is 
timely and will inform national HCV screening, treatment and 
prevention strategies.
Brief interventions targeting long-term benzodiazepine and 
Z-drug use in primary care: a systematic review and meta-
analysis
Lynch T, Ryan C, Hughes CM, et al. (2020) Addiction, Early online.
https://www.drugsandalcohol.ie/31589/ 
The aim of the study is to assess the effectiveness of 
brief interventions in primary care aimed at reducing or 
discontinuing long-term benzodiazepine/Z-drug (BZRA) use.
Brief interventions delivered in primary care are more effective 
than usual care in reducing and discontinuing long-term 
benzodiazepine/Z-drug use.
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